



RECEIVED

MAY 07 2001

TECH CENTER 1600/2900 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

#10/57 K.T.

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher

4/27/2001

Date of Deposit

Seg.

Amdt

B

w/B.O.T.
1 (10)

Applicant: Joyce, et al.)
Serial No.: 09/423,035) Group Art Unit: 1635
Filed: January 13, 2000) Examiner: A. Wang
Title: ENZYMATIC DNA MOLECULES) Our Ref.: TSRI 463.4
)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed March 16, 2001, enclosed is a Substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Substitute Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Substitute Sequence Listing is labeled SCR2190S.APP.

The enclosed Substitute Sequence Listing has been amended to more clearly define "n" in SEQ ID NOS 4, 23, 50, and 51.

I hereby state that the content of the paper and computer
05/04/2001 SZEWDIE1 00000060 09423035

01 FC:115


110.00 OP

readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

4/27/01

Date



Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937